Upload
abigail-hampton
View
219
Download
0
Tags:
Embed Size (px)
Citation preview
ANTIPLATELETES AGENTS
BY :DR. ISRAA OMAR
Platelets play a critical role in thromboembolic disease like ischemic heart disease and stroke
Platelets adhere to the diseased or damaged areas and become activated, exposing phospholipids and GPIIb/IIIa receptors.
Platelet change their shape to stellate form Activate platelets also synthesize and release mediators
like TXA2 and ADP, which stimulate other platelets to aggregate and eventually fibrin formation and thrombosis.
Platelet aggregation is inhibited by prostaglandin I2
TXA2 production is reduced by cAMP
The role of platelets
Aspirin inhibits COX-1 irreversibly, this will lead to inhibition of synthesis of thromboxane A2 which in turn lead to inhibition of platelet activation and aggregation.
Aspirin( Acetylsalicylic acid )
Aspirin (Acetylsalicylic acid) – mechanism of action
Acetylsalicylic acid – (Aspirin)mechanism of action
(Acetylsalicylic acid – (Aspirinmechanism of action
(Aspirin )Acetylsalicylic acid – mechanism of action
(Aspirin) Acetylsalicylic acid – mechanism of action
Rapid absorption of aspirin occurs in the stomach and upper intestine, with the peak plasma concentration being achieved 15-20 minutes after administration
The peak inhibitory effect on platelet aggregation is apparent approximately one hour post-administration
Aspirin produces the irreversible inhibition of the enzyme cyclooxygenase and therefore causes irreversible inhibition of platelets for the rest of their lifespan (7 days)
Aspirin– pharmacokinetics
Secondary prevention of transient ischaemic attack (TIA), ischaemic stroke and myocardial infarction
Prevention of ischaemic events in patients with angina pectoris
Prevention of coronary artery bypass graft (CABG) occlusion
Acetylsalicylic acid – major use
Risk of gastrointestinal adverse events (ulceration and bleeding)
Allergic reactions
Is not a very effective antithrombotic drug but is widely used because of its ease of use
Lack of response in some patients (aspirin resistance)
The irreversible platelet inhibition
(Aspirin )– major drawbacks
It inhibits platelets aggregation by irreversibly binding for ADP receptors on the surface of platelets.
This will lead to reduce mobilization of calcium from intracellular stores and reduces the expression of glycoprotein receptors on the platelets surface
2. Clopidogrel and Ticlodipine (Thienopyridines )
ADP-receptor antagonists – mechanism of action
ADP-receptor antagonists – mechanism of action
ADP-receptor antagonists – mechanism of action
ADP-receptor antagonists – mechanism of action
Both currently available ADP-receptor antagonists are thienopyridines that can be administered orally, and absorption is approximately 80-90%
Thienopyridines are pro-drugs that must be activated in the liver
ADP-receptor antagonists – pharmacokinetics
Secondary prevention of ischaemic complications after myocardial infarction, ischaemic stroke and established peripheral arterial disease
Secondary prevention of ischaemic complications in patients with acute coronary syndrome (ACS) without ST-segment elevation
ADP-receptor antagonists – major use
Clopidogrel is only slightly more effective than aspirin
As with aspirin, clopidogrel binds irreversibly to platelets
In some patients there is resistance to clopidogrel treatment
ADP-receptor antagonists – major drawbacks
Abciximab is a monoclonal antibody with Fc region removed to prevent immunogenicity .
It bind irreversibly to GPIIb/IIIa receptors and prevent its binding to fibrinogen .
It can reduce the platelets aggregation by more than 90% .
GPIIb/IIIa-receptor antagonists
GPIIb/IIIa-receptor antagonists – mechanism of action
GPIIb/IIIa-receptor antagonists – mechanism of action
GPIIb/IIIa-receptor antagonists – mechanism of action
GPIIb/IIIa-receptor antagonists – mechanism of action
GPIIb/IIIa-receptor antagonists – mechanism of action
Prevention of ischaemic cardiac complications in patients with acute coronary syndrome (ACS) without ST-elevation and during percutaneous coronary interventions (PCI), in combination with aspirin and heparin
GPIIb/IIIa-receptor antagonists – major use
It is a phosphodiaestrase inhibitor . It increases intracellular cyclic AMP, thus
reducing TXA2 synthesizes and also potentiate the prostacyclin effect on platelets making them less sticky and therefore making them less adhesive to thrombogenic surface .
It is ineffective when used alone; should be used with aspirin
It reduces the risk of stroke . Unlike aspirin it does not increase the risk of
bleeding
Dipyramole
Thank you
Lippincottes pharmacology Rang and dale pharmacology
Referrences: